INDUSTRY × Lung Neoplasms × Other solid neoplasm × Clear all
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

Phase 1/2 Recruiting
242 enrolled
NCT05461430 2025-09-15

TraveraRTGx

Travera Inc

Recruiting
200 enrolled
NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Incyte Corporation

Phase 1 Completed
260 enrolled 52 charts
NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 1 FDA
NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
NCT00413075 2015-07-08

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Valerio Therapeutics

Phase 1 Completed
121 enrolled
NCT00413322 2015-07-08

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Valerio Therapeutics

Phase 1 Completed
35 enrolled